X4 Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.17
- Today's High:
- $1.23
- Open Price:
- $1.23
- 52W Low:
- $0.65
- 52W High:
- $2.575
- Prev. Close:
- $1.24
- Volume:
- 1169590
Company Statistics
- Market Cap.:
- $213.75 million
- Book Value:
- 0.411
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $3 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -49.54%
- Return on Equity TTM:
- -267.24%
Company Profile
X4 Pharmaceuticals Inc had its IPO on 2017-11-16 under the ticker symbol XFOR.
The company operates in the Healthcare sector and Biotechnology industry. X4 Pharmaceuticals Inc has a staff strength of 40 employees.
Stock update
Shares of X4 Pharmaceuticals Inc opened at $1.23 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.17 - $1.23, and closed at $1.18.
This is a -4.84% slip from the previous day's closing price.
A total volume of 1,169,590 shares were traded at the close of the day’s session.
In the last one week, shares of X4 Pharmaceuticals Inc have slipped by -9.23%.
X4 Pharmaceuticals Inc's Key Ratios
X4 Pharmaceuticals Inc has a market cap of $213.75 million, indicating a price to book ratio of 1.0411 and a price to sales ratio of 53.8733.
In the last 12-months X4 Pharmaceuticals Inc’s revenue was $0 with a gross profit of $3 million and an EBITDA of $-100339000. The EBITDA ratio measures X4 Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, X4 Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -49.54% with a return of equity of -267.24%.
In Q2, X4 Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
X4 Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into X4 Pharmaceuticals Inc’s profitability.
X4 Pharmaceuticals Inc stock is trading at a EV to sales ratio of 50.056 and a EV to EBITDA ratio of -0.2521. Its price to sales ratio in the trailing 12-months stood at 53.8733.
X4 Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $173.40 million
- Total Liabilities
- $22.25 million
- Operating Cash Flow
- $-4884000.00
- Capital Expenditure
- $8000
- Dividend Payout Ratio
- 0%
X4 Pharmaceuticals Inc ended 2024 with $173.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $173.40 million while shareholder equity stood at $67.54 million.
X4 Pharmaceuticals Inc ended 2024 with $47.18 million in deferred long-term liabilities, $22.25 million in other current liabilities, 164000.00 in common stock, $-456470000.00 in retained earnings and $17.35 million in goodwill. Its cash balance stood at $136.43 million and cash and short-term investments were $141.31 million. The company’s total short-term debt was $1,912,000 while long-term debt stood at $31.84 million.
X4 Pharmaceuticals Inc’s total current assets stands at $147.65 million while long-term investments were $0 and short-term investments were $4.88 million. Its net receivables were $820000.00 compared to accounts payable of $5.11 million and inventory worth $0.
In 2024, X4 Pharmaceuticals Inc's operating cash flow was $-4884000.00 while its capital expenditure stood at $8000.
Comparatively, X4 Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.18
- 52-Week High
- $2.575
- 52-Week Low
- $0.65
- Analyst Target Price
- $3.66
X4 Pharmaceuticals Inc stock is currently trading at $1.18 per share. It touched a 52-week high of $2.575 and a 52-week low of $2.575. Analysts tracking the stock have a 12-month average target price of $3.66.
Its 50-day moving average was $1.55 and 200-day moving average was $1.36 The short ratio stood at 3.36 indicating a short percent outstanding of 0%.
Around 85.4% of the company’s stock are held by insiders while 6864.3% are held by institutions.
Frequently Asked Questions About X4 Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.